Drugs / Autologous apheresis Conventional untreated Platelet Components
Autologous apheresis Conventional untreated Platelet Components
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02653443 | Dec 2015 → May 2016 | — | Cerus Corporation | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous apheresis Conventional untreated Platelet Components | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02653443 ↗ |
| Route | Intravenous | “Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.” NCT02653443 ↗ |